Shares of the AdvisorShares Pure US Cannabis ETF (MSOS) climbed to their highest levels of 2026 this week, as investors position ahead of a June 29 administrative hearing that could reshape federal cannabis policy. The fund posted a 103.7% one-year net asset value return through May 31, dwarfing the North American Marijuana Index's 36.9% gain and the S&P 500's 29.8% return over the same stretch. Trulieve Cannabis, the ETF's largest holding at roughly 30% of assets, began trading on the NYSE under the ticker TRLV this week, a listing CEO Kim Rivers called a "historic milestone."
For multi-state operators watching from the sidelines, Trulieve's uplisting is less about one company's balance sheet and more about what it signals for capital access across the industry. Senior exchange listings bring institutional money, analyst coverage, and a lower cost of capital - all things cannabis operators have struggled to secure while stuck on over-the-counter markets. That matters operationally too: back-office systems built for compliance-heavy, cash-intensive retail need to scale alongside any new capital, and operators managing multiple dispensary formats increasingly rely on platforms like dispensary erp software illinois to keep inventory, tax reporting, and seed-to-sale tracking aligned as they grow. Trulieve's move followed a restructuring that separated its medical cannabis operations from its adult-use business, a step that reportedly helped it clear NYSE listing standards.
Why The Rescheduling Hearing Carries Weight
The upcoming hearing will examine whether cannabis products beyond state-licensed medical marijuana - including adult-use products - should move to Schedule III under federal law. Proceedings are expected to run through mid-July. This follows an April decision by Acting Attorney General Todd Blanche to reclassify state-licensed medical marijuana products, a move that eliminated the harshest tax penalties tied to Section 280E for licensed medical operators. Under 280E, cannabis companies have long been barred from deducting ordinary business expenses like payroll and rent because the product remains a Schedule I substance federally. Removing that penalty, even partially, changes the math on profitability for operators who've spent years absorbing effective tax rates far above what other retailers pay.
Trump's nomination of Blanche to serve as permanent attorney general has added to investor optimism that the rescheduling process will continue moving forward rather than stall. That's a real distinction worth sitting with - a proposed rule and a finalized one are not the same thing, and hearings can extend timelines well past initial expectations.
What Uplisting Actually Changes For Operators
Cresco Labs' new $50 million revolving credit facility from Needham Bank, secured this week, illustrates the kind of financing options opening up as banks grow more comfortable with cannabis risk. CEO Charlie Bachtell described it as a non-dilutive tool to fund acquisitions while positioning the company for a future senior exchange listing. That's the pattern worth watching across the sector: companies aren't just chasing rescheduling for tax relief, they're using it to unlock debt financing that was previously unavailable or prohibitively expensive.
- Schedule III reclassification would ease 280E tax burdens for state-licensed operators
- Senior exchange listings improve access to institutional capital and banking services
- Non-dilutive credit facilities are emerging as rescheduling anticipation builds
- The June 29 hearing outcome remains uncertain despite bullish market sentiment
Reading The Upside Numbers With Some Caution
Among MSOS holdings, Verano, Jushi Holdings, and Cresco Labs carry the highest analyst price-target upside, according to Koyfin data cited by AdvisorShares. Green Thumb Industries stands out among larger holdings with notably more upside than Trulieve or Curaleaf. Retail sentiment on platforms like Stocktwits has run "extremely bullish" on several of these names, with heavy message volume reflecting retail trader enthusiasm.
Here's the catch, though: price targets reflect analyst expectations, not guarantees, and cannabis equities have a track record of outrunning fundamentals when regulatory catalysts approach, then giving back gains when hearings get delayed or rulings disappoint. Operators and investors alike would do well to treat the June hearing as one data point in a longer regulatory process, not a finish line.
